A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 1, 2009, Pages 222-227

  Drappatz, Jan ^a,b   Wong, Eric T ^c   Schiff, David ^d   Kesari, Santosh ^a,b   Batchelor, Tracy T ^c   Doherty, Lisa ^a   LaFrankie, Debra Conrad ^a   Ramakrishna, Naren ^c   Weiss, Stephanie ^c   Smith, Sharon T ^a   Ciampa, Abigail ^a   Zimmerman, Jennifer ^a   Ostrowsky, Louis ^a   David, Karly ^a   Norden, Andrew ^a,b   Barron, Loretta ^c   Sceppa, Christine ^a   Black, Peter M ^e   Wen, Patrick Y ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Glioblastoma; Immunomodulatory; Lenalidomide; Radiotherapy

Indexed keywords

RADIOTHERAPY; TUMORS;

ANGIOGENESIS; ANTIANGIOGENIC; DOSE ESCALATIONS; GLIOBLASTOMA; GLIOBLASTOMA MULTIFORME; IMMUNOMODULATORY; LENALIDOMIDE; MAXIMUM TOLERATED DOSES; PILOT SAFETIES; REST PERIODS; TUMOR PROGRESSIONS; TUMOR RESPONSES;

TOXICITY;

ACETYLSALICYLIC ACID; LENALIDOMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOXIA; IMMUNOMODULATION; LUNG EMBOLISM; MALE; NAUSEA; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 57649110848     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.03.046     Document Type: Article

References (31)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Jensen R.L. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 20 (2006) E24
3. Brockmann M.A., Ulbricht U., Gruner K., et al. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52 (2003) 1391-1399 discussion 1399
4. Jain R.K., di Tomaso E., Duda D.G., et al. Angiogenesis in brain tumours. Nat Rev Neurosci 8 (2007) 610-622
5. Vacca A., Scavelli C., Montefusco V., et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23 (2005) 5334-5346
6. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 (1991) 699-703
7. Li X., Liu X., Wang J., et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23 (2003) 2481-2487
8. Krown S.E., Niedzwiecki D., Hwu W.J., et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107 (2006) 1883-1890
9. Fine H.A., Figg W.D., Jaeckle K., et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18 (2000) 708-715
10. Fine H.A., Wen P.Y., Maher E.A., et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21 (2003) 2299-2304
11. Chang S.M., Lamborn K.R., Malec M., et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60 (2004) 353-357
12. Mitsiades C.S., and Mitsiades N. CC-5013 (Celgene). Curr Opin Investig Drugs 5 (2004) 635-647
13. Dredge K., Horsfall R., Robinson S.P., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69 (2005) 56-63
14. Corral L.G., Haslett P.A., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 (1999) 380-386
15. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
16. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
17. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142
18. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
19. Fine H.A., Kim L., Royce C., et al. A phase I trial of CC-5103, a potent thalidomide analog, in patients with recurrent high-grade gliomas and other refractory CNS malignancies. [Abstract]. Proc Am Soc Clin Oncol 22 (2003) 105
20. Kayama T., Yoshimoto T., Fujimoto S., et al. Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 74 (1991) 55-59
21. Collingridge D.R., Piepmeier J.M., Rockwell S., et al. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 53 (1999) 127-131
22. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7 (2001) 987-989
23. Lee C.G., Heijn M., di Tomaso E., et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
24. Ansiaux R., Baudelet C., Jordan B.F., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11 (2005) 743-750
25. Marras L.C., Geerts W.H., and Perry J.R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89 (2000) 640-646
26. Macdonald D.R., Cascino T.L., Schold Jr. S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
27. Fine H.A., Kim L., Albert P.S., et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13 (2007) 7101-7106
28. Wong E., Hess K., Gleason M., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 (1999) 2572-2578
29. Bartlett J.B., Michael A., Clarke I.A., et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90 (2004) 955-961
30. Tohnya T.M., Ng S.S., Dahut W.L., et al. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer 2 (2004) 241-243
31. Niesvizky R., Naib T., Christos P.J., et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 138 (2007) 640-643